ReferenceRRK6353

Combined Phase 3 Double-blind Randomized Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease

Research Summary

Research Overview
PI Name Goh - J
Speciality
Sponsor Gilead Sciences
Project Status Open
Proposed End Date 31/03/2020
Study Run through CRF? No
Target number of patients agreed to recruit 3
Recruitment so far 0